Drug Trial Radar · NCT07265466
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Nov 17, 2025
Primary completion
Mar 30, 2026
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Conditions
- Drug Drug Interaction (DDI)
Interventions
JP-1366 and clopidogrelDrug
A randomized, open label, multiple-dosing, 6-sequence, 3-period, 3-treatment, crossover design
JP-1366 and aspirinDrug
An open-label, multiple-dosing, fixed sequence, 3-period design
JP-1366 and atorvastatinDrug
An open-label, multiple-dosing, fixed sequence, 3-period design Period 1: Atorvastatin
JP-1366 and apixabanDrug
An open-label, multiple-dosing, fixed sequence, 3-period design
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Part 1] Change in P2Y12 Reaction Unit (PRU) from baseline on day 8Time frame: baseline on day 8
- [Part 2] Emax of arachidonic acid-induced platelet aggregationTime frame: up to 48 hours post-dose on Day 1
- [Part 2] AUEC0-24 of arachidonic acid-induced platelet aggregationTime frame: up to 48 hours post-dose on Day 1
- [Part 2] Cmax,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
- [Part 2] AUCτ,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
- [Part 2] Cmax of AspirinTime frame: up to 48 hours post-dose on Day 1
- [Part 2] AUClast of AspirinTime frame: up to 48 hours post-dose on Day 1
- [Part 3] Cmax,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
- [Part 3] AUCτ,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
- [Part 3] Cmax,ss of AtorvastatinTime frame: up to 24 hours post-dose on Day 5
- [Part 3] AUCτ,ss of AtorvastatinTime frame: up to 24 hours post-dose on Day 5
- [Part 4] Emax of Anti-Factor Xa activityTime frame: up to 48 hours post-dose on Day 5
- [Part 4] AUEC0-12 of Anti-Factor Xa activityTime frame: up to 48 hours post-dose on Day 5
- [Part 4] Cmax,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
- [Part 4] AUCτ,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
- [Part 4] Cmax,ss of ApixabanTime frame: up to 12 hours post-dose on Day 5
- [Part 4] AUCτ,ss of ApixabanTime frame: up to 12 hours post-dose on Day 5
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cha University Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.